进行性多灶性白质脑病患者血浆JC病毒DNA的诊断与预后价值
该回顾性研究分析了103例进行性多灶性白质脑病患者及144例对照的血浆JC病毒(JCV)DNA,发现血浆JCV-DNA诊断PML的敏感度为48%、特异度为97%,且其水平与脑脊液水平和既往皮质类固醇治疗独立相关,在HIV阴性及接受cART的HIV阳性患者中较高血浆JCV-DNA水平与疾病进展相关。
要点
- 血浆JCV-DNA诊断PML的敏感度为48%、特异度为97%,在HIV阴性者中分别为83%和100%。
- 16例脑脊液JCV-DNA阴性的PML患者中,4例(25%)血浆JCV-DNA可检出。
- 血浆JCV-DNA水平与脑脊液水平独立相关(P < .0001),并与既往皮质类固醇治疗相关(P = .012)。
核心结论
- 检测血浆JCV-DNA可能补充PML诊断,尤其在脑脊液不可获得或脑脊液中JCV-DNA不可检出时。
- 血浆JCV-DNA水平可能作为HIV阴性和接受cART治疗的HIV阳性PML患者疾病进展的标志物。
研究设计与样本
- 回顾性分析PML患者发病附近采集的血浆样本及无PML对照的血浆样本。
- 共纳入103例PML患者和144例无PML对照。
主要发现
- 血浆JCV-DNA在49/103(48%)PML患者中检出(HIV阴性20/24,83%;HIV阳性29/79,37%),在4/144(3%)对照中检出(HIV阴性0/95;HIV阳性4/49,8%)。
- 诊断敏感度和特异度分别为48%和97%(HIV阴性83%和100%;HIV阳性37%和92%)。
- 16例脑脊液JCV-DNA不可检出的PML患者中,4例(25%)血浆JCV-DNA可检出。
- 血浆JCV-DNA水平与脑脊液水平独立相关(P < .0001),并与既往皮质类固醇治疗相关(P = .012)。
- 较高血浆JCV-DNA水平与HIV阴性患者疾病进展相关(P = .005);在HIV阳性患者中,仅在接受cART治疗者中与进展风险增加相关(P < .0001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease caused by the polyomavirus JC (John Cunningham; JCV) that affects patients with impaired immune systems. While JCV-DNA detection in cerebrospinal fluid (CSF) is diagnostic of PML, the clinical significance of plasma JCV-DNA is uncertain. METHODS: We retrospectively analyzed plasma samples from PML patients that were drawn close to disease onset and from controls without PML. In PML patients, we compared plasma JCV-DNA detection and levels to clinical and laboratory parameters, and patient survival. RESULTS: JCV-DNA was detected in plasma of 49/103 (48%) patients with PML (20/24, 83%, human immunodeficiency virus [HIV] negative; 29/79, 37%, HIV-positive) and of 4/144 (3%) controls without PML (0/95 HIV-negative; 4/49, 8%, HIV-positive), yielding a diagnostic sensitivity and specificity of 48% and 97% (83% and 100% in HIV-negative; 37% and 92% in HIV-positive), respectively. Among 16 PML patients with undetectable CSF JCV-DNA, 4 (25%) had detectable plasma JCV-DNA. Plasma JCV-DNA levels were independently associated with CSF levels (P < .0001) and previous corticosteroid treatment (P = .012). Higher plasma JCV-DNA levels were associated with disease progression in HIV-negative patients (P = .005); in HIV-positive patients, there was an increased risk of progression only in those treated with combination antiretroviral therapy (cART; P < .0001). CONCLUSIONS: Testing JCV-DNA in plasma might complement PML diagnosis, especially when CSF is unavailable or JCV-DNA not detectable in CSF. In addition, JCV-DNA plasma levels could be useful as a marker of disease progression in both HIV-negative and cART-treated, HIV-positive PML patients.
引用
- Ferretti F, Bestetti A, Yiannoutsos CT, et al. Diagnostic and Prognostic Value of JC Virus DNA in Plasma in Progressive Multifocal Leukoencephalopathy. Clin Infect Dis. 2018. PMID: 29346632. doi:10.1093/cid/ciy030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。